Inhibikase Therapeutics, Inc. (IKT) stock forecast and price target
Price $1.52 · data as of November 13, 2026
12-month price target
Average target$5.55
Upside / downside+265.1%
Analysts10
ConsensusStrong buy
Low $1.50Average $5.55High $8.00
Gold marker: average target · white marker: today’s price ($1.52)
Analyst ratings
Strong buy 1Buy 7Hold 1Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-0.40 | — | $0 |
| Next fiscal year ends December 31, 2027 | $-0.41 | −2.0% | $0 |
| Next quarter ends December 31, 2026 | $-0.10 | — | $0 |
| Quarter after ends March 31, 2027 | $-0.10 | — | $0 |
Consensus of the analysts covering Inhibikase Therapeutics, updated daily. In the last 30 days 0 estimates were raised and 1 lowered.
Frequently asked questions
What is the Inhibikase Therapeutics stock price target?
The average 12-month target from 10 analysts is $5.55, 265.1% above the current price of $1.52 Targets range from $1.50 to $8.00.
Is Inhibikase Therapeutics a buy according to analysts?
The consensus rating is “Strong buy” (1 strong buy, 7 buy, 1 hold). Ratings are opinions, not guarantees; this is not investment advice.
How much is Inhibikase Therapeutics expected to earn?
Analysts expect EPS of $-0.40 for the fiscal year ending December 31, 2026 and $-0.41 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.